Lineage Cell Therapeutics, Inc. Income Statement
LCTX|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Lineage Cell Therapeutics, Inc. reported $15M in revenue and $64M in net loss for FY2025. Revenue has grown at a 15.5% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $4.3M | $1.8M | $3.5M | $5.0M | $3.5M | $7.0M | $5.2M | $4.4M | $3.9M | $4.4M | $3.7M | $1.9M |
| Cost of Revenue | - | $334.0K | $671.0K | $1.4M | $385.0K | $412.0K | $302.0K | $168.0K | $1.1M | $837.0K | $793.0K | $434.3K | $79.4K | $27.7K | - |
| Gross Profit | - | - | $8.3M | $2.9M | $1.4M | $3.1M | $4.7M | $3.3M | $5.9M | $4.4M | $3.6M | $3.5M | $4.4M | $3.7M | - |
| SG&A Expense | $18.5M | $18.2M | $17.3M | $18.2M | $15.6M | $24.0M | $24.7M | $19.9M | $29.1M | $17.6M | $15.6M | $10.4M | $9.3M | $5.3M | -$2.3M |
| R&D Expense | $17.7M | $12.5M | $15.7M | $33.9M | $12.3M | $17.9M | $21.0M | $24.0M | $42.6M | $37.5M | $26.6M | $18.1M | $13.7M | $8.2M | -$3.2M |
| Operating Income | -$36.6M | -$21.5M | -$24.7M | -$49.2M | -$26.4M | -$38.9M | -$41.8M | -$38.9M | -$65.8M | -$50.7M | -$56.0M | -$25.0M | -$18.7M | -$9.9M | -$3.5M |
| Interest Expense | - | - | - | $2.0K | $1.0M | - | - | - | - | - | $0 | $19.4K | $29.7K | -$124.3K | -$1.7M |
| Income Tax | -$5.3M | $0 | -$1.8M | $541.0K | -$1.2M | -$7.4M | $346.0K | -$346.0K | - | - | - | - | - | - | - |
| Net Income | -$63.5M | -$18.6M | -$21.5M | -$43.0M | -$20.6M | -$11.7M | -$46.0M | -$20.0M | -$47.0M | -$36.4M | -$43.9M | -$21.4M | -$16.5M | -$11.2M | -$5.1M |
| EPS (Basic) | -$0.09 | -$0.12 | -$0.15 | -$0.26 | -$0.01 | -$0.06 | $0.30 | -$0.50 | -$0.59 | -$0.55 | - | - | - | - | - |
| EPS (Diluted) | -$0.09 | -$0.12 | -$0.15 | - | -$0.14 | -$0.08 | -$0.36 | -$0.17 | -$0.59 | -$0.55 | -$0.81 | -$0.44 | -$0.35 | -$0.28 | -$0.18 |
| Shares Outstanding | 220.4M | 175.0M | 170.1M | 169.5M | 153.1M | 149.8M | 127.1M | 126.9M | 102.8M | 90.4M | 78.2M | 56.7M | 49.4M | 49.0M | 47.8M |
| Gross Margin | - | - | 92.5% | 67.2% | 78.9% | 88.3% | 94.0% | 95.1% | 84.3% | 84.0% | 82.1% | 88.9% | 98.2% | 99.3% | - |
| Operating Margin | -251.6% | -226.1% | -276.5% | -1133.6% | -1448.4% | -1106.0% | -837.9% | -1125.0% | -935.3% | -966.5% | -1262.7% | -638.5% | -421.4% | -265.7% | -182.9% |
| Profit Margin | -436.5% | -195.9% | -240.2% | -991.0% | -1130.8% | -333.1% | -922.0% | -577.7% | -667.9% | -694.4% | -989.7% | -547.2% | -372.5% | -301.6% | -267.2% |